Psychedelics Investing Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
Psychedelics Investing Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History
Psychedelics Investing Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global
Psychedelics Investing Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
Psychedelics Investing Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors
Psychedelics Investing Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health
Psychedelics Investing Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients
Psychedelics Investing Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle
Psychedelics Investing Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre
Psychedelics Investing Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA
Psychedelics Investing Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
Life Science Investing Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers
